WST West Pharmaceutical Services Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
08:00
Jul 23
Jul 23
Management raised full-year guidance significantly, citing broad-based strength in HVP components, GLP-1s, and biologics, with operating margin expansion exceeding 200 bps.
HIGH
20:34
Jul 14
Jul 14
West Pharmaceutical Services and Daikyo Seiko entered amended cross-license and distributorship.
West Pharmaceutical Services and Daikyo Seiko entered amended cross-license and distributorship agreements with West maintaining 49% ownership in Daikyo covering joint development and know-how sharing for pharmaceutical packaging under a 10-year term.
22:20
Jul 01
Jul 01
West Pharma delivers durable healthcare exposure.
West Pharmaceutical provides elastomeric components for injectable drugs, serving all pharma companies and not dependent on individual drug approvals; it is a durable, reliable business with stable earnings, a better bet than companies heavily tied to data center buildout.
HIGH
20:31
Mar 10
Mar 10
"Long term CEO Eric Green plans to retire. This marking the second recent exact change after announcing the hiring of a new CFO last year." Clustered C-suite turnover—especially losing both a CEO and CFO within a short window—often signals underlying operational challenges, internal disagreements, or an impending strategic pivot. Institutional investors hate uncertainty and typically sell into major leadership vacuums. SHORT. The stock is already struggling (down 15% YTD), and executive instability will further weigh on investor sentiment and forward visibility. The new management team quickly implements a successful turnaround strategy that accelerates growth.
08:00
Feb 12
Feb 12
Management guides FY2026 revenue and EPS growth, citing momentum from HVP components and margin expansion, while embedding conservative GLP-1 assumptions.
HIGH
08:00
Oct 23
Oct 23
Management raised full-year guidance, citing re-accelerating demand in HVP components, strong GLP-1 and Annex 1 tailwinds, and improving market conditions. The tone is confident about a sustainable recovery and margin expansion into 2026.
HIGH
About WST Analyst Coverage
Buzzberg tracks WST (West Pharmaceutical Services) across 3 sources. 1 bullish vs 0 bearish calls from 5 analysts. Sentiment: predominantly bullish (17%). 6 total trade ideas tracked. Latest voices: Bob McMahon, FirstSquawk, Julie Biel.